exo-IWR-1, an inactive stereoisomer of Endo-IWR-1, is a negative control of IWR-1 (HY-12238). IWR-1 is a tankyrase inhibitor which inhibits Wnt/β-catenin signaling pathway^[1][2].

exo-IWR-1 (10 μM) does not influence the number of 293T cells infected with bunyaviruses^[1].
Exo-IWR-1 had no effect on RVFV MP12-GFP infection when cells were either pretreated or treated 1 hpi^[2].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

409.44

C₂₅H₁₉N₃O₃

1127442-87-8

Room temperature in continental US; may vary elsewhere.

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

In Vitro: 

DMSO : 2 mg/mL (4.88 mM; ultrasonic and warming and heat to 60°C)

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

• [1]. Brooke Hamion, et al. Genome-wide RNA Interference Screen Identifies Novel Drug Targets for Rift Valley Fever Virus That Minimi the Potential for Drug Resistance.

  [2]. Brooke Harmon, et al. A Genome-Wide RNA Interference Screen Identifies a Role for Wnt/β-Catenin Signaling during Rift Valley Fever Virus Infection. J Virol. 2016 Jul 27;90(16):7084-7097.